An Aged/Autoimmune B-cell Program Defines the Early Transformation of Extranodal Lymphomas

Overview

Journal Cancer Discov

Specialty Oncology

Date 2022 Oct 20

PMID 36264161

Authors

Leandro Venturutti

Martin A Rivas

Benedikt W Pelzer

Ruth Flumann

Julia Hansen

Ioannis Karagiannidis

Min Xia

Dylan R McNally

Yusuke Isshiki

Andrew Lytle

Matt Teater

Christopher R Chin

Cem Meydan

Gero Knittel

Edd Ricker

Christopher E Mason

Xiaofei Ye

Qiang Pan-Hammarstrom

Christian Steidl

David W Scott

Hans Christian Reinhardt

Alessandra B Pernis

Wendy Beguelin

Ari M Melnick

Affiliations

Soon will be listed here.

Abstract

Significance: Extranodal lymphomas feature a very poor prognosis. The identification of phenotypically distinguishable prospective precursor cells represents a milestone in the pursuit of earlier diagnosis, patient stratification, and prophylactic interventions. Conceptually, we found that extranodal lymphomas and autoimmune disorders harness overlapping pathogenic trajectories, suggesting these B-cell disorders develop and evolve within a spectrum. See related commentary by Leveille et al. (Blood Cancer Discov 2023;4:8-11). This article is highlighted in the In This Issue feature, p. 1.

Citing Articles

Identification, risk factors, and clinical course of CNS relapse in DLBCL patients across 19 prospective phase 2 and 3 trials-a LYSA and GLA/ DSHNHL collaboration.

Frontzek F, Renaud L, Duhrsen U, Poeschel V, Bernard S, Chartier L Leukemia. 2024; 38(10):2225-2234.

PMID: 39152324 DOI: 10.1038/s41375-024-02371-y.

The Diverse Roles of ETV6 Alterations in B-Lymphoblastic Leukemia and Other Hematopoietic Cancers.

Monovich A, Gurumurthy A, Ryan R Adv Exp Med Biol. 2024; 1459:291-320.

PMID: 39017849 DOI: 10.1007/978-3-031-62731-6_13.

Mouse models of diffuse large B cell lymphoma.

Tabatabai A, Arora A, Hofmann S, Jauch M, von Tresckow B, Hansen J Front Immunol. 2023; 14:1313371.

PMID: 38124747 PMC: 10731046. DOI: 10.3389/fimmu.2023.1313371.

Extranodal lymphoma: pathogenesis, diagnosis and treatment.

Yang H, Xun Y, Ke C, Tateishi K, You H Mol Biomed. 2023; 4(1):29.

PMID: 37718386 PMC: 10505605. DOI: 10.1186/s43556-023-00141-3.

Diffuse large B-cell lymphoma involving the central nervous system: biologic rationale for targeted therapy.

Roschewski M, Hodson D Haematologica. 2023; 109(2):388-400.

PMID: 37706315 PMC: 10828633. DOI: 10.3324/haematol.2021.278613.

References

Ricker E, Manni M, Flores-Castro D, Jenkins D, Gupta S, Rivera-Correa J . Altered function and differentiation of age-associated B cells contribute to the female bias in lupus mice. Nat Commun. 2021; 12(1):4813. PMC: 8355159. DOI: 10.1038/s41467-021-25102-8. View

Varettoni M, Zibellini S, Arcaini L, Boveri E, Rattotti S, Pascutto C . MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance. Blood. 2013; 122(13):2284-5. DOI: 10.1182/blood-2013-07-513366. View

Chapuy B, Roemer M, Stewart C, Tan Y, Abo R, Zhang L . Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2015; 127(7):869-81. PMC: 4760091. DOI: 10.1182/blood-2015-10-673236. View

Singh M, Jackson K, Wang J, Schofield P, Field M, Koppstein D . Lymphoma Driver Mutations in the Pathogenic Evolution of an Iconic Human Autoantibody. Cell. 2020; 180(5):878-894.e19. DOI: 10.1016/j.cell.2020.01.029. View

Chapuy B, Stewart C, Dunford A, Kim J, Kamburov A, Redd R . Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018; 24(5):679-690. PMC: 6613387. DOI: 10.1038/s41591-018-0016-8. View

Cuttner J, Spiera H, Troy K, Wallenstein S . Autoimmune disease is a risk factor for the development of non-Hodgkin's lymphoma. J Rheumatol. 2005; 32(10):1884-7. View

Mareschal S, Lanic H, Ruminy P, Bastard C, Tilly H, Jardin F . The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age. Haematologica. 2011; 96(12):1888-90. PMC: 3232277. DOI: 10.3324/haematol.2011.050617. View

Holmes A, Corinaldesi C, Shen Q, Kumar R, Compagno N, Wang Z . Single-cell analysis of germinal-center B cells informs on lymphoma cell of origin and outcome. J Exp Med. 2020; 217(10). PMC: 7537389. DOI: 10.1084/jem.20200483. View

Suan D, Krautler N, Maag J, Butt D, Bourne K, Hermes J . CCR6 Defines Memory B Cell Precursors in Mouse and Human Germinal Centers, Revealing Light-Zone Location and Predominant Low Antigen Affinity. Immunity. 2017; 47(6):1142-1153.e4. DOI: 10.1016/j.immuni.2017.11.022. View

10.

Phalke S, Marrack P . Age (autoimmunity) associated B cells (ABCs) and their relatives. Curr Opin Immunol. 2018; 55:75-80. DOI: 10.1016/j.coi.2018.09.007. View

11.

Venturutti L, Melnick A . The dangers of déjà vu: memory B cells as the cells of origin of ABC-DLBCLs. Blood. 2020; 136(20):2263-2274. PMC: 7702481. DOI: 10.1182/blood.2020005857. View

12.

Lu C, Chen J, Huang T, Wu Y, Chang P, Dai M . Diffuse large B-cell lymphoma: sites of extranodal involvement are a stronger prognostic indicator than number of extranodal sites in the rituximab era. Leuk Lymphoma. 2014; 56(7):2047-55. DOI: 10.3109/10428194.2014.982636. View

13.

Cattoretti G, Buttner M, Shaknovich R, Kremmer E, Alobeid B, Niedobitek G . Nuclear and cytoplasmic AID in extrafollicular and germinal center B cells. Blood. 2006; 107(10):3967-75. DOI: 10.1182/blood-2005-10-4170. View

14.

Ye X, Wang L, Nie M, Wang Y, Dong S, Ren W . A single-cell atlas of diffuse large B cell lymphoma. Cell Rep. 2022; 39(3):110713. DOI: 10.1016/j.celrep.2022.110713. View

15.

Jain N, Hartert K, Tadros S, Fiskus W, Havranek O, Ma M . Targetable genetic alterations of () drive immunoglobulin expression in diffuse large B cell lymphoma. Sci Transl Med. 2019; 11(497). PMC: 6724184. DOI: 10.1126/scitranslmed.aav5599. View

16.

Venturutti L, Teater M, Zhai A, Chadburn A, Babiker L, Kim D . TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory Fate. Cell. 2020; 182(2):297-316.e27. PMC: 7384961. DOI: 10.1016/j.cell.2020.05.049. View

17.

An B, Zhu S, Li T, Wu J, Zang G, Lv X . A Dual TLR7/TLR9 Inhibitor HJ901 Inhibits ABC-DLBCL Expressing the MyD88 L265P Mutation. Front Cell Dev Biol. 2020; 8:262. PMC: 7188833. DOI: 10.3389/fcell.2020.00262. View

18.

Niroula A, Sekar A, Murakami M, Trinder M, Agrawal M, Wong W . Distinction of lymphoid and myeloid clonal hematopoiesis. Nat Med. 2021; 27(11):1921-1927. PMC: 8621497. DOI: 10.1038/s41591-021-01521-4. View

19.

Lee J, Jeong H, Choi J, Oh H, Kim Y . Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis. Sci Rep. 2017; 7(1):1785. PMC: 5431939. DOI: 10.1038/s41598-017-01998-5. View

20.

Jeong H, Cho H, Kim H, Chae H, Lee J, Lee K . Efficacy and safety of prophylactic high-dose MTX in high-risk DLBCL: a treatment intent-based analysis. Blood Adv. 2021; 5(8):2142-2152. PMC: 8095148. DOI: 10.1182/bloodadvances.2020003947. View